Literature DB >> 1829366

Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users.

G H Mientjes1, F Miedema, E J van Ameijden, A A van den Hoek, P T Schellekens, M T Roos, R A Coutinho.   

Abstract

To investigate whether drug use affected immunological parameters, we conducted a cross-sectional study of 321 drug users. Absolute numbers of CD4+ lymphocytes and the T-cell reactivity were lower in HIV-positive than in HIV-negative people. The functional capacity of the T-cell system as measured after stimulation with a monoclonal antibody directed against CD3 was found to be strongly associated with the frequency of injecting, while no relationship was found between the frequency of injecting and the total number of lymphocytes or T-cell subsets. HIV-negative and HIV-positive drug users who had injected a mean of three times a day in the preceding 4-6 months had a T-cell reactivity which was 40-50% lower compared with seronegative and with seropositive drug users who had not injected in the preceding months. We conclude that lymphocyte reactivity is depressed by frequent injecting in HIV-negative and HIV-positive drug users.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829366     DOI: 10.1097/00002030-199101000-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  14 in total

1.  Methadone programmes. The costs and benefits to society and the individual.

Authors:  G E Ralston; P Wilson
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 2.  Aspergillus endophthalmitis: a clinical and experimental study.

Authors:  A A Aziz; J D Bullock; T W McGuire; B L Elder; J W Funkhouser
Journal:  Trans Am Ophthalmol Soc       Date:  1992

3.  Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution?

Authors:  V V Lukashov; J Goudsmit
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users.

Authors:  F Montella; P Pezzotti; F Di Sora; O Recchia; F Lauria; G Rezza
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

5.  Slow progression to AIDS in intravenous drug users infected with HIV in Norway.

Authors:  A Eskild; P Magnus; C Sohlberg; P Kittelsen; J H Olving; B Teige; K Skullerud
Journal:  J Epidemiol Community Health       Date:  1994-08       Impact factor: 3.710

6.  High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs.

Authors:  M-J Milloy; Brandon Marshall; Thomas Kerr; Lindsey Richardson; Robert Hogg; Silvia Guillemi; Julio S G Montaner; Evan Wood
Journal:  Drug Alcohol Rev       Date:  2014-11-11

7.  Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362.

Authors:  Susan E Cohn; Hongyu Jiang; J Allen McCutchan; Susan L Koletar; Robert L Murphy; Kevin R Robertson; Annabelle M de St Maurice; Judith S Currier; Paige L Williams
Journal:  AIDS Care       Date:  2011-06

Review 8.  Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review.

Authors:  Michael-John S Milloy; Brandon D L Marshall; Thomas Kerr; Jane Buxton; Tim Rhodes; Julio Montaner; Evan Wood
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

9.  Clinical symptoms associated with seroconversion for HIV-1 among misusers of intravenous drugs: comparison with homosexual seroconverters and infected and non-infected intravenous drug misusers.

Authors:  G H Mientjes; E J van Ameijden; H M Weigel; J A van den Hoek; R A Coutinho
Journal:  BMJ       Date:  1993-02-06

10.  Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users.

Authors:  L S Brown; N S Siddiqui; A F Chu
Journal:  J Natl Med Assoc       Date:  1996-01       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.